Scientist.com Launches Clinical Labs Navigator™ to Expand Clinical Sourcing Capabilities
'Clinical Labs Navigator was built to meet the increasing need for integrated, efficient, and compliant solutions in clinical trial execution,' said Matt McLoughlin, SVP of Compliance & Categories at Scientist.com. 'We've created a tool that not only helps clients streamline the design of clinical trials, through enhanced internal and external collaboration, but increases transparency throughout the study design and contracting process.'
The solution enhances platform workflows across several high-impact areas for both the sponsor and CRO:
Budget Digitization: Improved budget tracking and rate card adherence
Budget Management: Built-in cost modeling tools to improve and refine accuracy of budget estimates
Increased compliance: Enhanced audit trails to increase efficiency and compliance
Enhanced analytics: Improved reporting capabilities across various metrics
With this release, Scientist.com expands its clinical-stage portfolio to offer solutions across the entire development pipeline including Health Economics and Outcomes Research (HEOR), Real-World Evidence/Data (RWE/RWD), Market Access, GMP manufacturing, and late-stage biomarker development. Clinical Labs Navigator is particularly suited for organizations seeking to consolidate sourcing efforts, reduce study delays, and increase visibility across their global clinical operations.
The launch is a key milestone in Scientist.com's broader mission to digitally transform the way research is conducted. By leveraging AI-enabled tools and deeply embedded compliance frameworks, the platform empowers researchers and procurement professionals to make smarter, faster decisions—ultimately accelerating the development of life-changing therapies.
To learn more about Clinical Labs Navigator™ and explore our full suite of clinical sourcing solutions, visit https://info.scientist.com/clinical
Scientist.com is the leading AI-enabled digital research platform for the life science industry. The platform simplifies drug discovery and development by streamlining procurement, accelerating innovation, ensuring regulatory compliance, and connecting researchers with a global network of pre-qualified suppliers. Scientist.com powers private marketplaces for the world's largest pharmaceutical companies, over 100 biotech firms, and the US National Institutes of Health (NIH). Learn more at Scientist.com.
[email protected]
SOURCE: Scientist.com
Copyright Business Wire 2025.
PUB: 04/08/2025 07:55 AM/DISC: 04/08/2025 07:55 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates. 'In the first half of 2025, we made significant progress in our NGN-401 program for Rett syndrome. We completed dosing of the last five participants in the Phase 1/2 trial and received written agreement from the U.S. FDA on the key elements of the Embolden™ registrational trial, in which we have already begun initiation activities,' stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. 'We are pleased to be moving forward with Embolden, which was purposefully and rigorously designed to differentiate NGN-401 by evaluating participants as young as three years of age with a primary endpoint that incorporates measures that KOLs, caregivers and payors believe to be clinically meaningful. Our previously announced reallocation of capital provides us runway into early 2028, enabling us to focus our resources on advancement of this potential therapy for the patients and families who urgently need new treatment options.' Dr. McMinn continued, 'In leveraging the continual dialogue under the START program, the FDA encouraged the analysis of the Embolden primary endpoint to remain at 12 months as the basis for full approval, noting that a 6-month endpoint may not be considered clinically meaningful. In further maintaining the rigorous design of the Embolden trial, we are electing to dose the last planned participant from the Phase 1/2 trial as part of the registrational Embolden trial and add one more participant to complete the proposed sample size at 20 patients.' Second Quarter 2025 and Recent Highlights, and Anticipated Milestones NGN-401 Gene Therapy for Treatment of Rett Syndrome Received written agreement from the U.S. Food and Drug Administration (FDA) on key elements of the Embolden registrational trial of NGN-401 and refined the sample size to propose 20 participants Initiated Embolden clinical trial activities to support the conversion of the Phase 1/2 trial to a registrational trial Completed enrollment in the Phase 1/2 trial, with the last 5 additional participants dosed in the first half of 2025 Remains on track to report updated clinical efficacy and safety data from the Phase 1/2 trial in the second half of 2025 Presented at scientific conferences the hemophagocytic lymphohistiocytosis (HLH) monitoring and treatment algorithm incorporated into the NGN-401 clinical trial, which has been acknowledged as valuable information by the Rett syndrome and gene therapy communities There has been no evidence of HLH/hyperinflammatory syndrome in any NGN-401 trial participant at the 1E15 vg dose level, as of the date of this press release Upcoming Events Stifel Biotech Summer Summit: Management will participate in a fireside chat at 12:00 p.m. ET on August 12 (not webcast) H.C. Wainwright Annual Global Investment Conference: Management will participate in a fireside chat at 2:30 p.m. ET on September 8 and participate in 1x1 meetings Second Quarter 2025 Financial Results Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of June 30, 2025 were $274.5 million. We currently expect cash, cash equivalents and short-term investments to fund planned operations into early 2028. Research & Development (R&D) Expenses: R&D expenses were $19.4 million for the three months June 30, 2025 compared to $15.7 million for the three months ended June 30, 2024. The increase in R&D expenses for the three months ended June 30, 2025 was primarily driven by an increase in Rett syndrome clinical trial costs and employee-related expenses due to an increase in R&D headcount. General & Administrative (G&A) Expenses: G&A expenses were $6.7 million for the three months ended June 30, 2025 compared to $5.3 million for the three months ended June 30, 2024. The increase in G&A expenses for the three months ended June 30, 2025 was primarily driven by an increase in employee-related expenses due to an increase in stock-based compensation, headcount and other corporate expenses. Net Loss: Net loss was $22.0 million for the three months ended June 30, 2025 compared to $18.5 million for the three months ended June 30, 2024. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit About NGN-401 NGN-401 is an investigational AAV9 gene therapy being developed as a one-time treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT™ transgene regulation technology. EXACT technology is an important advancement in gene therapy for Rett syndrome, specifically because the disorder requires a treatment approach that enables targeted levels of MECP2 transgene expression without causing overexpression-related toxic effects associated with conventional gene therapy. NGN-401 was selected by the U.S. Food and Drug Administration (FDA) for its START Pilot Program and has also received Regenerative Medicine Advance Therapy (RMAT) designation, orphan drug designation, Fast Track designation and rare pediatric designation from the FDA. Neurogene was previously granted an INTERACT meeting with the FDA regarding the EXACT technology. NGN-401 also received Priority Medicines (PRIME) designation, orphan designation and advanced therapy medicinal product designation from the European Medicines Agency (EMA) and the Innovative Licensing and Application Pathway (ILAP) designation from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Cautionary Note Regarding Forward-Looking Statements Statements in this press release are made as of the date of this press release. Neurogene does not undertake any obligation to make any updates to these statements to reflect events that occur or circumstances that arise after the date of this press release, except as may be required under applicable U.S. securities law. Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: the therapeutic potential and utility, efficacy and clinical benefits of NGN-401; trial designs, clinical development plans and timing for NGN-401, including elements of the registrational clinical study trial design subject to final approval of the FDA, such as the proposed number of participants in the Embolden trial, and the timing of the conversion of the NGN-401 Phase 1/2 clinical trial to a registrational clinical trial, anticipated timing of additional updates for the Embolden registrational trial of NGN-401 for Rett syndrome; expected timing for additional interim data from the Company's NGN-401 Phase 1/2 trial for Rett Syndrome, expected future interactions with or positions of the FDA; and the time period over which existing cash resources may be sufficient to fund the Company's operations. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' 'on track,' and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene's control. Such risks, uncertainties and assumptions include, among other things: the expected timing of additional results from the NGN-401 clinical trial; the potential for negative impacts to participants in the Phase 1/2 clinical trial of NGN-401 for the treatment of Rett syndrome; the risk that the Company may not be able to report data on the predicted timeline; risks related to the Company's ability to obtain regulatory approval for, and ultimately commercialize, its product candidates, including NGN-401; risks related to timing of initiating the Embolden trial of NGN-401 for Rett syndrome; and other risks and uncertainties identified under the heading "Risk Factors" included in Neurogene's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission ('SEC') on August 11, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This communication contains hyperlinks to information that is not deemed to be incorporated by reference into this communication. - Financial Tables Follow - Neurogene Inc. Condensed Consolidated Statements of Operations (In thousands of U.S. dollars, except share information) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue under licensing agreements — 925 — 925 Operating expenses: Research and development expenses 19,366 15,744 37,131 29,285 General and administrative expenses 6,715 5,315 14,869 10,553 Total operating expenses 26,081 21,059 52,000 39,838 Loss from operations (26,081 ) (20,134 ) (52,000 ) (38,913 ) Other income, net 4,065 1,642 7,337 3,500 Net loss $ (22,016 ) $ (18,492 ) $ (44,663 ) $ (35,413 ) Per share information: Net loss per share, basic and diluted $ (1.05 ) $ (1.09 ) $ (2.12 ) $ (2.09 ) Weighted-average shares of common stock outstanding, basic and diluted 21,055,378 16,941,524 16,922,630 Expand
Yahoo
5 hours ago
- Yahoo
Red Hat OpenShift Named a Leader for Third Consecutive Year in 2025 Gartner® Magic Quadrant™ for Container Management
Red Hat is recognized as a Leader in the Magic Quadrant. Red Hat believes this affirms its foundational role in enterprise container strategies across the hybrid cloud. RALEIGH, N.C., August 11, 2025--(BUSINESS WIRE)--Red Hat, the world's leading provider of open source solutions, today announced that it has been named a Leader for the third consecutive year in the 2025 Gartner Magic Quadrant for Container Management. Red Hat OpenShift, the industry's leading hybrid cloud application platform powered by Kubernetes, was recognized for the solution's Completeness of Vision and in Ability to Execute in the Magic Quadrant. In our opinion, this consistent recognition highlights Red Hat OpenShift's unwavering ability to provide a comprehensive and robust platform for container management across diverse IT environments. It underscores Red Hat's commitment to offering operational consistency and standardization for organizations adopting cloud-native approaches. Red Hat OpenShift empowers enterprises to standardize, automate and scale their container initiatives across any footprint, from the datacenter to multiple cloud environments and the edge. The platform's integrated security features, advanced management capabilities and strong focus on developer productivity enable IT teams to accelerate application modernization and deliver business value more rapidly. The Gartner Magic Quadrant for Container Management evaluated 15 vendor solutions and was based on specific criteria that analyzed the company's overall completeness of vision and ability to execute. According to Gartner, Leaders execute well against their current vision and are well positioned for tomorrow. View a complimentary copy of the Magic Quadrant report to learn more about Red Hat's strengths and cautions, among other provider offerings, here. This report follows the Gartner recognition of the Red Hat as a Leader in the most recent 2025 Gartner Magic Quadrant for Cloud-Native Application Platforms. Supporting Quotes Mike Barrett, vice president & general manager, Hybrid Cloud Platforms, Red Hat "We believe being recognized as a Leader for the third consecutive year in the Gartner Magic Quadrant for Container Management validates Red Hat OpenShift's role as a cornerstone for modern IT strategies. Our platform empowers enterprises to standardize, automate and scale their container initiatives across any footprint, from the datacenter to multiple cloud environments, providing the flexibility and control needed to meet evolving business demands." Additional Resources Learn more about Red Hat OpenShift Check out the blog to learn more: Red Hat Named a Leader in 2025 Gartner® Magic Quadrant™ for Container Management for the Third Consecutive Year Connect with Red Hat Learn more about Red Hat Get more news in the Red Hat newsroom Read the Red Hat blog Follow Red Hat on X Follow Red Hat on Instagram Watch Red Hat videos on YouTube Follow Red Hat on LinkedIn Gartner Disclaimer Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. About Red Hat, Inc. Red Hat is the open hybrid cloud technology leader, delivering a trusted, consistent and comprehensive foundation for transformative IT innovation and AI applications. Its portfolio of cloud, developer, AI, Linux, automation and application platform technologies enables any application, anywhere—from the datacenter to the edge. As the world's leading provider of enterprise open source software solutions, Red Hat invests in open ecosystems and communities to solve tomorrow's IT challenges. Collaborating with partners and customers, Red Hat helps them build, connect, automate, secure and manage their IT environments, supported by consulting services and award-winning training and certification offerings. Forward-Looking Statements Except for the historical information and discussions contained herein, statements contained in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the company's current assumptions regarding future business and financial performance. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially. Any forward-looking statement in this press release speaks only as of the date on which it is made. Except as required by law, the company assumes no obligation to update or revise any forward-looking statements. Red Hat, Red Hat Enterprise Linux, the Red Hat logo, and OpenShift are trademarks or registered trademarks of Red Hat, Inc. or its subsidiaries in the U.S. and other countries. Linux® is the registered trademark of Linus Torvalds in the U.S. and other countries. View source version on Contacts Media Contact: Chelsea Lawrenceclawrenc@ +1 (252) 622-8406 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 hours ago
- Business Wire
Elucid's PlaqueIQ ™ Image Analysis Software Now Covered by United Healthcare
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced that United Healthcare has updated its cardiac imaging guidelines to fully align with recent recommendations from radiology benefit manager EviCore. United Healthcare's new guidelines now include coronary computed tomography angiography (CTA) plaque quantification (see page 520), specifically encompassing Elucid's PlaqueIQ™ technology. The coverage will apply to all United Healthcare plans beginning October 1, 2025. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology. PlaqueIQ delivers automated quantification and classification of plaque morphology, and is uniquely capable of identifying and quantifying lipid rich necrotic core, a plaque type strongly linked with cardiovascular risk. 1,2 The software is designed to help physicians prioritize and personalize treatment based on actual coronary artery disease, rather than population-based risk. This technology supports physicians in evaluating treatment of patients' symptoms and risk of future cardiac events, such as heart attack and stroke, and enables the development of personalized care pathways informed by each patient's individual plaque characteristics. 'United Healthcare's new e guidelines further underscore the need for better tools to help clinicians get ahead of heart attack and stroke,' said Elucid CEO Kelly Huang, PhD. 'With its basis in CT Virtual Histology™, we believe that PlaqueIQ is poised to make a meaningful difference towards this goal.' United Healthcare's updated guidelines align with recently issued guidelines by radiology benefit manager EviCore. In addition to the recent coverage decision by United Healthcare, a new CMS rule went into effect on January 1, 2025, which doubled the amount paid to hospitals and outpatient clinics who perform cardiac CT scans from $175 to $357.13. This has allowed more hospitals, particularly those in non-urban areas, to be able to offer this service, reducing disparities in care. In late 2024, five of the seven Medicare Administrative Contractors (MACs) issued decisions to extend coverage of Elucid's PlaqueIQ, making it available to over 70 percent of eligible Medicare patients across the United States. The newly assigned Category I code for coronary plaque analysis, which goes into effect on January 1, 2026, complements the recent coverage decisions by United Healthcare and EviCore, allowing for expanded patient access and personalized treatment for patients with coronary artery disease (CAD). About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
